← Back to Search

Stem Cell Therapy

CPCB-RPE1 for Macular Degeneration

Phase 1 & 2
Waitlist Available
Research Sponsored by Regenerative Patch Technologies, LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights

Summary

This trial tests a new treatment using special cells on a thin film to help patients with severe vision loss from advanced dry AMD. The cells are implanted into the eye to repair and support damaged tissue, potentially slowing or stopping further vision loss. Recent studies have shown the potential of this approach in repairing the degenerated retina in AMD.

Eligible Conditions
  • Macular Degeneration
  • Age-Related Macular Degeneration

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Frequency and Severity of Treatment-Related Adverse Events [Safety and Tolerability]
Secondary study objectives
Photoreceptor Electrical Responses
Visual Acuity
Visual Field

Trial Design

1Treatment groups
Experimental Treatment
Group I: CPCB-RPE1 treatmentExperimental Treatment1 Intervention
Subretinal implantation of CPCB-RPE1 in dry AMD patients

Find a Location

Who is running the clinical trial?

Regenerative Patch Technologies, LLCLead Sponsor
1 Previous Clinical Trials
24 Total Patients Enrolled
1 Trials studying Macular Degeneration
24 Patients Enrolled for Macular Degeneration
Jane Lebkowski, Ph.D.Study DirectorRegenerative Patch Technologies
~2 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top